Context is king, whether you’re telling an amusing anecdote or poring over raw data, and without it, it’s hard to know what to make of anything. A Medicare payment transparency effort may be lacking context, and experts tell me it may be reducing the effectiveness of the program.
The Open Payments program requires drug and device companies to report all payments to doctors and teaching hospitals, and Medicare posts a yearly update June 30. In 2016, for example, drug and device companies made $8.19 billion in payments to doctors and teaching hospitals.
Major questions remain over whether the reported Open Payments data is accurate or detailed enough to provide any real insights to patients or the government, Andrew Furlow, an attorney with Hogan Lovells in New York, told me. “There’s a persistent misconception in some circles that all payments being reported are inherently improper,” he said.
Furlow said a recent New Jersey rule capping payments from drug companies to doctors at $10,000 is an example of the context problem. A press release touting the new rule cited the total amount paid by drug companies to New Jersey doctors as the reason for the cap, he told me.
“This kind of inference is troubling and may call for education at the state level to ensure policy makers understand the data and what it represents,” Furlow said.
Inaccurate data can easily be reported through the Open Payments program, a spokesman for the American Medical Association told me, and there’s little chance that it will be verified and corrected. Physicians have to register with the program to review data and have a chance to dispute inaccurate records.
The Centers for Medicare & Medicaid Services doesn’t validate the data it receives from drug and device companies, and physicians frequently aren’t aware of the reported data, the AMA said.
Only 5.5 percent of physicians registered for the Open Payments program, according to the 2016 data.
Read my full story here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)